Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$4.94B+10.77%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shervin J. Korangy
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 108,165
- Beta
- 0.76
- Country
- DE
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.69
Financials
Revenue
$4.94B+10.8%Net Income
$159.78M-61.9%EBITDA
$400.13M-57.8%Free Cash Flow
$559.59M+108.0%EPS (diluted)
$0.31-47.5%Shares Outstanding (diluted)
524.00M-14.6%Operating Expenses
$785.00MCash & Debt
$1.10BReturn of Capital
$284.18MRevenue by Segment (annual)
$17.51BDividend per Share
$0.86Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $19.63B | $978.37M | $1.68 |
| 2024 | $19.34B | $537.91M | $0.92 |
| 2023 | $19.45B | $499.00M | $0.85 |
| 2022 | $19.40B | $673.40M | $0.57 |
| 2021 | $17.62B | $969.31M | $0.83 |
| 2020 | $17.86B | $1.16B | $1.31 |
| 2019 | $17.48B | $1.20B | $1.35 |
| 2018 | $16.55B | $1.98B | $3.23 |
| 2017 | $17.78B | $1.28B | $2.08 |
| 2016 | $17.03B | $1.18B | $1.87 |
| 2015 | $15.31B | $941.19M | $1.57 |
| 2014 | $13.02B | $859.37M | $1.43 |
| 2013 | $10.58B | $803.76M | $1.33 |
| 2012 | $10.43B | $897.39M | $1.48 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from FMS's reported EPS growth of 1.0% a year over 13 years.
- EPS in 5 years
- $1.77
- Implied price
- $21.19
- Return from $20.13
- 1.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $10.53 — -47.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 8 | 10 | 12 | 14 | 16 |
|---|---|---|---|---|---|
| -9.0% | -16.1% | -12.2% | -9.0% | -6.1% | -3.6% |
| -4.0% | -11.5% | -7.4% | -4.0% | -1.0% | 1.7% |
| 1.0% | -6.8% | -2.6% | 1.0% | 4.2% | 7.0% |
| 6.0% | -2.2% | 2.2% | 6.0% | 9.4% | 12.3% |
| 11.0% | 2.4% | 7.1% | 11.0% | 14.5% | 17.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-69.70%Social Signal Score
Mentions (11)
- Newsmarketbeat.com·18d ago·Neutral
What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported broadly stable third-quarter revenue and a decline in operating income as reimbursement pressures and inflation weighed on results, while the company continued to advance its U.S. rollout of high-volume hemodiafiltration technology and execute its share repurchase program.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript
View source ↗ - Newsreuters.com·19d ago·Neutral
Fresenius Medical cuts top end of 2026 profit outlook Fresenius Medical cuts top end of 2026 profit outlook
View source ↗ - Newszacks.com·30d ago·Neutral
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
View source ↗ - Newsprnewswire.com·32d ago·Positive
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™ Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment for acute kidney injury Integrated technology helps hospital intensive care teams deliver compl
View source ↗ - Newsbusinesswire.com·32d ago·Negative
Fly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS LAS VEGAS--(BUSINESS WIRE)--flyExclusive, Inc. (NYSE American: FLYX), one of the nation's largest private jet operators, today announced that Fly Alliance has agreed to replace its existing flight management system across its entire operation with Contrails FMS, flyExclusive's free, AI-powered aviation operating platform.The announcement, made at NBAA-BACE 2026, represents a significant milestone…
View source ↗ - Newszacks.com·46d ago·Neutral
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.
View source ↗ - Newszacks.com·54d ago·Positive
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
View source ↗ - Newszacks.com·80d ago·Neutral
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase? Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
View source ↗ - Newszacks.com·80d ago·Positive
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
View source ↗ - Newsyoutube.com·95d ago·Positive
3 Cheap International Stocks to Buy These stocks have economic moats and look attractive today.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $0.54 per share
Typical surprise +4.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.64 vs $0.65miss
- Mon, Aug 3$0.66 vs $0.62beat
- Tue, May 5$0.53 vs $0.59miss
- Tue, Feb 24$0.83 vs $0.65beat
- Tue, Nov 4$0.64 vs $0.59beat
- Tue, Aug 5$0.52 vs $0.50beat
Estimates and results for FMS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FMS officers and directors.
No open-market trades in the recent filings. All 1 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (41d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (41d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 27, 2022 (44d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (31d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (31d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 30, 2021 (56d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 30, 2021 (56d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 25, 2021 (42d later)Buy$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 25, 2021 (42d later)Buy$50,001 - $100,000
- Dean Phillipshouse · MN03 · disclosed Feb 13, 2021 (33d later)Buy$1,001 - $15,000
- Dean Phillipshouse · MN03 · disclosed Feb 13, 2021 (32d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Feb 8, 2019 (37d later)Sell$100,001 - $250,000
- Greg Gianfortehouse · MT00 · disclosed Jan 23, 2019 (33d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 4, 2019 (14d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Dec 11, 2018 (21d later)Sell$50,001 - $100,000
- Greg Gianfortehouse · MT00 · disclosed Jul 9, 2018 (4d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
